Apollomics (APLM) Stock Price, Quote, News & History

Comments

Apollomics Inc (APLM) Stock Price, Quote, News & History

APLMNASDAQ

Trade with Public

$21.40

3.6020.22%

Last update: Feb 24, 8:11 AM

OverviewNews Earnings Analyst Ratings Short Interest Stock Report

Key Statistics

Open

$18.47

Close

-

Volume / Avg.

505.00 / 14.39K

Day Range

$18.47 - $18.47

52 Wk Range

3.66 - 42.12

Market Cap

$45.95M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

0.65%

Days to Cover

2.31

Recent Apollomics Inc News

Dow Dips Over 300 Points; Walmart Raises FY25 Forecast

Avi Kapoor

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Dow Falls 100 Points; Brady Posts Upbeat Results

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-20.38M

Investing Cash Flow (TTM)

284.00K

Financing Cash Flow (TTM)

-3.73M

Free Cash Flow (TTM)

-20.38M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-23.83M

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$36.87M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

2.31

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-149.66%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$2.05

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

-$133.00K

Total Cash

$2.09M

Debt to Equity

-

Issuance of Debt (TTM)

-$133.00K

Repayment of Debt (TTM)

-$3.64M

Key Statistics

Open

$18.47

Close

-

Volume / Avg.

505.00 / 14.39K

Day Range

$18.47 - $18.47

52 Wk Range

3.66 - 42.12

Market Cap

$45.95M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

0.65%

Days to Cover

2.31

About

Sector

Health Care

Industry

Biotechnology

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pat...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Apollomics (APLM) stock?

A

You can purchase shares of Apollomics (NASDAQ:APLM) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Apollomics (APLM) competitors?

A

Other companies in Apollomics’s space includes: Serina Therapeutics Inc (AMEX:SER), Estrella Immunopharma Inc (NASDAQ:ESLA), Evaxion AS (NASDAQ:EVAX), Aligos Therapeutics Inc (NASDAQ:ALGS) and Sensei Biotherapeutics Inc (NASDAQ:SNSE).

Q

What is the forecast, or price target, for Apollomics (APLM) stock?

A

Apollomics has a consensus price target of $8.50.

Q

What is the current price for Apollomics (APLM)?

A

The stock price for Apollomics (NASDAQ: APLM) is $21.4 last updated February 24, 2026 at 8:11 AM EST.

Q

Does Apollomics (APLM) pay a dividend?

A

There are no upcoming dividends for Apollomics.

Q

When is Apollomics (NASDAQ:APLM) reporting earnings?

A

Apollomics does not have any upcoming earnings scheduled.

Q

Is Apollomics (APLM) going to split?

A

There is no upcoming split for Apollomics.

Q

What sector and industry does Apollomics (APLM) operate in?

A

Apollomics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Serina Therapeutics Inc

AMEX:SER

$2.62

-16.83%

Estrella Immunopharma Inc

Aligos Therapeutics Inc

NASDAQ:ALGS

$6.80

-1.02%

Sensei Biotherapeutics Inc

NASDAQ:SNSE

$32.38

-1.22%

Palatin Technologies Inc

AMEX:PTN

$23.70

1.02%

Lisata Therapeutics Inc

Key Statistics

Open

$18.47

Close

-

Volume / Avg.

505.00 / 14.39K

Day Range

$18.47 - $18.47

52 Wk Range

3.66 - 42.12

Market Cap

$45.95M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

0.65%

Days to Cover

2.31

Recent Apollomics Inc News

Dow Dips Over 300 Points; Walmart Raises FY25 Forecast

Avi Kapoor

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Dow Falls 100 Points; Brady Posts Upbeat Results

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-20.38M

Investing Cash Flow (TTM)

284.00K

Financing Cash Flow (TTM)

-3.73M

Free Cash Flow (TTM)

-20.38M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-23.83M

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$36.87M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

2.31

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-149.66%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$2.05

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

-$133.00K

Total Cash

$2.09M

Debt to Equity

-

Issuance of Debt (TTM)

-$133.00K

Repayment of Debt (TTM)

-$3.64M

Key Statistics

Open

$18.47

Close

-

Volume / Avg.

505.00 / 14.39K

Day Range

$18.47 - $18.47

52 Wk Range

3.66 - 42.12

Market Cap

$45.95M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

0.65%

Days to Cover

2.31

About

Sector

Health Care

Industry

Biotechnology

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pat...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry